# A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

> **NCT00724334** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 42 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** SAR302503 (TG101348)

## Key facts

- **NCT ID:** NCT00724334
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724334, "A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00724334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*